Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
VEGF signaling pathway | R-HSA-194138 | map04370 | proguanil | 3242 | drug-path |
Bladder cancer | R-HSA-9700206 | map05219 | proguanil | 3242 | drug-path |
Long-term potentiation | R-HSA-9620244 | map04720 | proguanil | 3242 | drug-path |
ErbB signaling pathway | R-HSA-168638 | map04012 | proguanil | 3242 | drug-path |
Non-small cell lung cancer | R-HSA-5619066 | map05223 | proguanil | 3242 | drug-path |
ECM-receptor interaction | R-HSA-373711 | map04512 | proguanil | 3242 | drug-path |
Endometrial cancer | R-HSA-2077421 | map05213 | proguanil | 3242 | drug-path |
GnRH signaling pathway | R-HSA-168638 | map04912 | proguanil | 3242 | drug-path |
Colorectal cancer | R-HSA-4791275 | map05210 | proguanil | 3242 | drug-path |
Vascular smooth muscle contraction | R-HSA-445355 | map04270 | proguanil | 3242 | drug-path |
T cell receptor signaling pathway | R-HSA-983705 | map04660 | risperidone | 5073 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | risperidone | 5073 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | risperidone | 5073 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | risperidone | 5073 | drug-path |
Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | tribenoside | 196122 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | tribenoside | 196122 | drug-path |
Axon guidance | R-HSA-422475 | map04360 | tribenoside | 196122 | drug-path |
Bladder cancer | R-HSA-9700206 | map05219 | tribenoside | 196122 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | tribenoside | 196122 | drug-path |
Pathways in cancer | R-HSA-9824443 | map05200 | tribenoside | 196122 | drug-path |